Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Gerger, S.
Analysis of distribution, incidence and survival of chordoma patients in the United States from 2000 to 2010
Humanmedizin; [ Diplomarbeit ] Medical University of Graz; 2014. pp. 66
[OPEN ACCESS]
FullText
- Autor*innen der Med Uni Graz:
- Betreuer*innen:
- Leithner Andreas
- Riedl Regina
- Altmetrics:
- Abstract:
- Introduction: Chordoma is a slow growing highly recurrent malignant tumor that arises from remnants of the notochord. It constitutes 1-4% of all primary malignant bone tumors. Due to the rare occurrence the number of studies concerning incidence and survival on this form of cancer is limited. Methods: With the use of the most recent dataset from the Surveillance Epidemiology and End Results (SEER) program of the National Cancer Institute we conducted a retrospective analysis calculating distribution and incidence patterns for 795 cases of microscopically confirmed chordoma from 2000 to 2010. Furthermore we analysed outcome to determine relevant prognostic factors for survival. The World Health Organization’s ICD-O3 morphological codes for chordoma (9370/3 chordoma NOS, 9371/3 chondroid chordoma, 9372/3 dedifferentiated chordoma) were used to identify the cases. We calculated frequencies, age-adjusted incidence rates and relative survival (RS) rates using the statistical software SEER*Stat. Cases were analysed by gender, age, race, Hispanic origin, primary site of presentation, tumor size and treatment. For mortality calculations and further statistical tests, SAS 9.2 was used. Results: The overall age-adjusted incidence rate for chordoma was 0.9 per million population. We observed higher rates in males than in females and lower rates in blacks than in whites. The most common site of presentation was the cranial region. In addition, younger age, Hispanic origin and small tumor size (<5cm) were associated with greater likelihood of cranial presentation. Large tumor size (= 5cm) was most common in sacral sites. 5- and 10-year relative survival was found to be 78% and 57%, respectively. Concerning prognostic factors, younger age, cranial presentation and surgery were significantly associated with a better outcome. Small tumor size also showed a trend towards better prognosis. Survival, however, was not influenced by sex, race, Hispanic origin and radiation therapy. Conclusion: With 18 registries included in the most recent dataset of the SEER program this study provides the latest series of chordoma cases with substantial information concerning incidence and survival patterns of chordoma in the United States including relevant prognostic factors.